Literature DB >> 12172573

Burkitt s lymphoma variant of post-transplant lymphoproliferative disease (PTLD).

Melissa A Pasquale1, Debbie Weppler, Jon Smith, Michael Icardi, Alexandra Amador, Monica Gonzalez, Tomoaki Kato, Andreas Tzakis, Phillip Ruiz.   

Abstract

The occurrence of posttransplant lymphoproliferative disorder (PTLD) in solid organ allograft recipients can be quite varied in clinical presentation, histopathological characteristics and frequency. A variety of lymphomas can develop as a PTLD although some types appear infrequently and remain poorly understood in this clinical setting. In this report, we describe two cases of Burkitt s lymphoma presenting as a PTLD following liver transplantation. The recipients were 12 and 44 years of age and displayed gastrointestinal involvement by the tumors several years following transplant. The tumors displayed the typical histological features of Burkitt s lymphoma and were markedly positive for EBV. The tumors displayed similar immunophenotypic characteristics by flow cytometry and had rearrangements of the immunoglobulin J-H heavy chain. The tumors required aggressive chemotherapy and a cessation of immunosuppressive therapy. This report demonstrates that Burkitt s type lymphomas can develop in the posttransplant setting and that these tumors contain morphologic, cytofluorographic and molecular features identical to Burkitt s lymphomas that occur in non-transplant patients. Our experience is that these PTLD- Burkitt s lymphomas behave aggressively and require intensive chemotherapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172573     DOI: 10.1007/bf03033718

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Histopathology       Date:  2000-01       Impact factor: 5.087

2.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

3.  Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop.

Authors:  N L Harris; J A Ferry; S H Swerdlow
Journal:  Semin Diagn Pathol       Date:  1997-02       Impact factor: 3.464

4.  Histopathological definition of Burkitt's tumour.

Authors: 
Journal:  Bull World Health Organ       Date:  1969-04       Impact factor: 9.408

5.  Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.

Authors:  V Leblond; L Sutton; R Dorent; F Davi; M O Bitker; J Gabarre; F Charlotte; J J Ghoussoub; C Fourcade; A Fischer
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

6.  Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.

Authors:  T V Cacciarelli; M Green; R Jaffe; G V Mazariegos; A Jain; J J Fung; J Reyes
Journal:  Transplantation       Date:  1998-10-27       Impact factor: 4.939

7.  Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus.

Authors:  D Frank; E Cesarman; Y F Liu; R E Michler; D M Knowles
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

8.  Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern.

Authors:  J F Malatack; J C Gartner; A H Urbach; B J Zitelli
Journal:  J Pediatr       Date:  1991-05       Impact factor: 4.406

9.  The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children.

Authors:  M Ho; R Jaffe; G Miller; M K Breinig; J S Dummer; L Makowka; R W Atchison; F Karrer; M A Nalesnik; T E Starzl
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

10.  Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; T Cacclarelli; J McMichael; J Rakela; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

View more
  5 in total

Review 1.  The management of posttransplant lymphoproliferative disorder.

Authors:  Noelle V Frey; Donald E Tsai
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Orbital sporadic Burkitt lymphoma in an adult diabetic African American female and a review of adult orbital cases.

Authors:  John Carmody; Raghunath P Misra; Marlyn P Langford; William A Byrd; Lauren Ditta; Bryan Vekovius; Donald E Texada
Journal:  Clin Ophthalmol       Date:  2011-04-20

3.  Epstein Barr Virus-positive large T-cell lymphoma presenting as acute appendicitis 17 years after cadaveric renal transplant: a case report.

Authors:  Shiva K Ratuapli; Shishir Murarka; Karen A Miller; James C Ferraro; Haider Zafar
Journal:  J Med Case Rep       Date:  2011-01-12

4.  PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis.

Authors:  A Stravodimou; A Cairoli; T Rausch; R Du Pasquier; P Michel
Journal:  Case Rep Med       Date:  2012-01-19

5.  Burkitt's Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature.

Authors:  Seema Naik; Kristy Tayapongsak; Katherine Robbins; Cyrus Koresh Manavi; Mark J Pettenati; David D Grier
Journal:  Case Rep Oncol       Date:  2013-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.